Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Larimar Therapeutics Q4 EPS $(0.30) Misses $(0.25) Estimate, Cash Position $86.8M

Author: Benzinga Newsdesk | March 14, 2024 04:15pm
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.25) by 20 percent. This is a 42.86 percent decrease over losses of $(0.21) per share from the same period last year.

Posted In: LRMR

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist